Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1897-908. Unique Identifier : AIDSLINE MED/93143999
Zwart G; Wolfs TF; Valk M; Van der Hoek L; Kuiken CL; Goudsmit J; Human Retrovirus Laboratory, Academic Medical Center, Amsterdam,; The Netherlands.


Abstract: The major neutralization domain of HIV-1, contained in the third variable region (V3) of the external envelope, is highly variable at positions flanking a conserved glycine-proline-glycine sequence. We investigated the relation between V3 sequences of HIV-1 variants circulating in a host and that host's antibody specificity. Multiple V3 sequences were obtained directly, via PCR and subsequent cloning, from serum RNA or cellular DNA from 26 individuals (from 12 around seroconversion). Then, specificity of sera from these individuals to a panel of V3 peptides was determined. The specificity (best recognized peptide) of the early antibody response accurately reflected the virus population circulating around seroconversion in 12/12 individuals and 4/4 HIV-1-infected chimpanzees. A change in serum specificity at later stages of infection was rare: five years after seroconversion, only 3 of 46 individuals had a specificity that differed completely from that in the first year. However, the V3 domain of the virus does change over time, as evidenced by the poor correlation between V3 sequences obtained late in infection and V3 antibody reactivity at the same time point. Thus, in contrast to the accurate antibody response to HIV-1 variants early after infection, generally a specific response to variants emerging at later stages seemed to be absent or of low level. Instead, the early response appeared to be preserved. Finally, we made use of the observed accurate reflection to analyze the variation for the V3 domain of HIV-1 in the Netherlands by probing specificities of early sera from 129 Dutch seroconverting individuals. Specific reactivity to RKSIHIGPGRAFYTTG was found in 36%, to RKSINIGPGRAFYTTG in 12% and to RKSIPIGPGRAFYTTG in 18% of these Dutch sera.
Keywords: Amino Acid Sequence Animal Antibody Specificity/*IMMUNOLOGY Binding, Competitive Chimpansee troglodytes Consensus Sequence Enzyme-Linked Immunosorbent Assay Human HIV Envelope Protein gp120/*IMMUNOLOGY HIV Seropositivity/EPIDEMIOLOGY/*IMMUNOLOGY HIV-1/*IMMUNOLOGY IgG/IMMUNOLOGY Longitudinal Studies Male Molecular Sequence Data Netherlands/EPIDEMIOLOGY Neutralization Tests Peptide Fragments/CHEMICAL SYNTHESIS/IMMUNOLOGY Serotyping/METHODS Support, Non-U.S. Gov't Time Factors JOURNAL ARTICLEKWDaminoacidsequenceanimalantibodyspecificity/KWDimmunologybinding,competitivechimpanseetroglodytesconsensussequenceenzyme-linkedimmunosorbentassayhumanhivenvelopeproteingp120/KWDimmunologyhivseropositivity/epidemiology/KWDimmunologyhiv-1/KWDimmunologyigg/immunologylongitudinalstudiesmalemolecularsequencedatanetherlands/epidemiologyneutralizationtestspeptidefragments/chemicalsynthesis/immunologyserotyping/methodssupport,non-uKWDsKWDgov'ttimefactorsjournalarticle
930530
M9350970

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .